Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001

NCT00775073 is registered in ClinicalTrials.gov with Gerhard Treiber as lead sponsor.

NCT NCT00775073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00775073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001
Lead sponsor
Gerhard Treiber
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
April 30, 2012
Enrollment
33 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma